FOI requests, and the information they reveal, are an important element of Senate Estimates. In the past, a reference to the FOI number would prompt a staff member to appear with the relevant information to enable discussion. At the start of my question, a staff member approached the table with their laptop open—most likely with the FOI document displayed—so that system still exists. Nonetheless, Professor Lawler avoided discussing the FOI.
Some Senators provide their questions in advance so the FOI can be ready, however this also gives the witness time to prepare an evasive answer and removes the possibility of an unguarded admission. The point of my question was simple: the TGA’s own guidelines—which the FOI meeting notes confirmed—state that single-use medicines and vaccines should not contain preservatives. That unguarded admission is exactly what I was referring to. Professor Lawler stated that preservatives relate to multi-dose vaccines, not single-dose vaccines.
This is the argument I will make moving forward. At the last Estimates, I reviewed data that clearly linked preservatives in vaccines with autism. Single-use vaccines do not contain preservatives (or should not). Why don’t we immediately return to administering vaccines in single-use doses that are certified and tested as preservative and contaminant free? Then we can monitor autism cases in real time.
Many mothers have told me their child’s autism began the day after their shots. This approach would quickly show us whether there is a link in the real world. Let’s take a simple, immediate step to address this issue, and then conduct a full review of vaccine safety and efficacy.
— Senate Estimates | December 2025
Transcript
Senator ROBERTS: I reference freedom of information 26-2122, released 30 September 2025. It’s weirdly specific: the minutes of the pharmaceutical subcommittee of the advisory committee on prescriptions. I think that’s part of the TGA. Is that correct?
Mr Comley: That sounds to me like PBAC.
Prof. Lawler: Can I clarify which committee you referenced?
Senator ROBERTS: Yes: the pharmaceutical subcommittee of the advisory committee on prescriptions. They’ll be coming to the TGA pretty soon.
Prof. Lawler: No. We have a number of advisory committees, but we don’t have an advisory committee on prescriptions. We have an advisory committee on medicines and an advisory committee on vaccines.
Senator ROBERTS: Perhaps if I give you the question you might be able to tell me. Held on 24 March 2015 and regarding the matter of preservatives in single-use injections, the meeting concluded: … single-use injections should be preservative-free. … if an ingredient is added for a reason other than use as a preservative, then the sponsor should provide scientific justification for inclusion at that concentration. Is this guideline still current?
Prof. Lawler: I must admit I don’t have that document in front of me, so I’m finding it hard to respond to that on the fly.
Senator ROBERTS: You can take it on notice.
Prof. Lawler: I’m happy to do that. The best I can take it is that we look to preservatives predominantly for multi-use vials because, obviously, there’s a period between them being used first—but I’m happy to take that on notice and come back to you.
Senator ROBERTS: It sounds like the answer to the question, ‘Is this guideline still current?’ is correct, but I’m not going to hold it to you. Thank you for that. The next questions, possibly also on notice, are: have you allowed any single-use injection product to contain preservatives, and were all of those approvals compliant with your own guidelines?
Prof. Lawler: Again, given the first question, I’m happy to respond to that on notice, if that’s alright.
Senator ROBERTS: And could you provide the list of any that were approved. If you have allowed single-use injections to contain preservatives, why did you make the change to allow preservatives when your expert committee opposed the idea?
Prof. Lawler: My understanding is that the committee you’re referencing—what was the date of the—
Senator ROBERTS: It was 24 March 2015—probably before your time.
Prof. Lawler: It was well before my time. That is an older committee. I think, in the interest of providing you with a comprehensive response, we’d be happy to roll those up into one response, if that’s alright.
Senator ROBERTS: I’d just like to know if it’s still current.
Prof. Lawler: Absolutely.
Senator ROBERTS: I’d like to know this too: Which multidose vaccines contain preservatives? Have you obtained safety data to show those preservatives are safe at the levels used?
Prof. Lawler: There are a number of branches across the TGA and also, potentially, ATAGI to which those questions apply.
Senator ROBERTS: Sure.
Dr Pengilley: To the best of my knowledge, the only use of preservatives in multi-use vials is for pandemic vaccines, and that, at the moment, is the influenza ones; COVID, just for clarity, doesn’t contain preservatives. We haven’t—
Senator ROBERTS: It does or doesn’t contain—
Dr Pengilley: Does not. I probably can’t go into applications we have and haven’t had, but, as far as I know, we haven’t registered a preservative-containing pandemic vaccine—say, an H5N1 vaccine.
This exchange during Senate Estimates with the Therapeutic Goods Administration (TGA) sums up just how bad Estimates has become under the Albanese Labor Government.
The TGA is well aware that Senators only have a few minutes to ask questions, and they understand that the more they can stall, the less likely it is they’ll have to say anything that could cause problems for their Minister—regardless of the truth. Because of this, the Minister will not require the “witness” to answer the question, nor will the Committee Chair—both of whom are Labor Senators.
My first question was a genuine attempt to clarify misinformation circulating online about aluminium intake. The answer was a simple “yes.” Keep that in mind when you watch the video. Instead of confirming the obvious and allowing us to move on to another question about aluminium in vaccines, the opportunity was taken to stall for time by debating whether the question should even be asked at all. Dr. Lawler, Deputy Secretary of the Health Products Regulation Group within the Department of Health, oversees the agencies and committees the Government uses to spread responsibility, avoiding accountability. He was exactly the right person to direct these questions to.
The data I presented was straightforward: the level of aluminium in vaccines is unsafe for infants by an order of magnitude. Yet the TGA spent a great deal of time on their pre-prepared responses insisting that vaccines are safe. They refuse to accept any data showing that this level of exposure is causing health issues in infants. I then asked whether our vaccines had been subject to gold standard testing—a term used on many occasions by “witnesses” attending Estimates to defend COVID vaccines – yet suddenly, the gold standard is no longer relevant to … vaccines! Suddenly, testing a product against a double-blind placebo (saline) is now considered “unsafe,” despite this being the standard for a century?
In reality, what Big Pharma has been doing for years—and what the TGA has allowed them to do in Australia—is to compare new vaccines (or medications for that matter) against existing ones, rather than saline. If the harm detected is the same as that already being caused by the “placebo” medication, it’s deemed safe. This is not how things should be.
I will continue this line of questioning until we get a proper inquiry into the level of heavy metal contamination in infant vaccines.
— Senate Estimates | October 2025
Transcript
Senator ROBERTS: Thank you for being here again, especially Professor Lawler. Before I start, can we deal with a statement I hear on the internet all the time—that you get more aluminium in your food than you do in vaccines. Aluminium in food is ingested at 0.3 per cent. In vaccines, it’s ingested at 100 per cent. Individual results may vary. Is this a fair statement?
Prof. Lawler: I’m not sure where you’re seeing that. I don’t have the information you’re referencing in front of me.
Senator ROBERTS: I’m asking you whether it’s accurate.
Prof. Lawler: I’m not sure that is necessarily a question for the TGA to respond to. We can provide you with information on the process that we undertake in terms of the evaluation and authorisation of therapeutic goods, including vaccines. Is this a claim that the TGA has made?
Senator ROBERTS: No. That’s my understanding. What is the TGA’s recommended maximum daily intake of aluminium for a child aged six months, please?
Prof. Lawler: By mouth as a recommended daily intake?
Senator ROBERTS: Yes.
Prof. Lawler: I don’t believe that the TGA sets a recommended daily ingestion of aluminium, Senator.
Senator ROBERTS: What is the daily maximum for a child of six months that can ingest aluminium in food?
Prof. Lawler: I would suggest that those are probably questions best posed to Food Standards Australia New Zealand, Senator.
Senator ROBERTS: The US Food and Drug Administration recommends exposure of five micrograms per kilogram in infants. At six months, the average weight of an infant is seven kilograms, making the maximum daily exposure 35 micrograms. The Infanrix hexa vaccine contains 825 micrograms of aluminium per dose, which is 24 times its safe daily limit. Do you accept injecting children at 23 times the safe level? Do you accept that this unsafe aluminium exposure is a contributing factor to aluminium derived autism?
Prof. Lawler: I will throw to Dr Dascombe in a moment. I will answer a couple of the things there in reverse order, if I may. The first is that, in answer to your second question, no. I don’t believe that there is a recognised regulator—I’m happy to be corrected—that does.
Senator ROBERTS: Rather than relying on someone else, do you have any data or research?
Prof. Lawler: I’m just trying to answer your question. I don’t believe that there is another regulator. I’m just using that as back-up. We have seen no credible safety signal that aluminium load either in single or scheduled immunisation delivery is a contributor to autism. The second thing I would say is that I am not sure this is the forum, nor do we have the time, to clarify the distinction between injected and ingested aluminium. They are quite different biomechanical processes. I don’t think the two are comparable. I will ask Dr Dascombe to add to that answer.
Dr Dascombe: I echo the comments of Professor Lawler. Neither the TGA nor any international regulator has detected or confirmed any safety signals relating to any vaccine and autism. This is also supported by the weight of scientific evidence.
Senator ROBERTS: What is the TGA guidance for the injection of multiple vaccines into a six-month-old at the same time causing amplified aluminium? Each of those doses has aluminium adjuvant, a preservative, so each of them is 24 times the daily safe limit.
Prof. Lawler: My apologies for breaking in, Senator. There are a couple of points on that. It is not the practice or the role of the TGA to make recommendations on immunisation schedules. That sits within the province of ATAGI, the Australian Technical Advisory Group on Immunisation. I would also highlight that we have frequently responded to questions around the aluminium load in the vaccination schedule and their consequences. Most recently, but perhaps more recently, is a Senate question on notice 24-003075. We have discussed it in this place a number of times.
Senator ROBERTS: You see the problem. Just one vaccine can be 24 times over the safe daily limit. You are recommending injecting multiple of them at the same time. These infants could be getting over 100 times the safe limit and you just keep on injecting them right in there and then claim aluminium poisoning isn’t the reason they come down with autism in some cases the very next day. How can you justify this?
Prof. Lawler: I will answer those questions in reverse order, if I may. I will answer the second. There is no indication that the vaccination schedule is linked to autism. Indeed, it has been highlighted not just today but previously. There’s no credible evidence that there is a linkage between vaccination and autism. As I just indicated in my previous answer, it is not the role of the TGA to recommend vaccinations. We assess them for safety, quality and efficacy. It’s the role of ATAGI to recommend the vaccination schedules.
Senator ROBERTS: Why don’t you tell the pharma companies to reduce the aluminium preservatives down to safe levels so you can get parents to trust your vaccine again and the parents can trust your advice again?
Prof. Lawler: There are a couple of elements in your question. We evaluate the submissions from sponsors and evaluate the process of manufacture and quality control to ensure that the balance of risk versus benefit is appropriate. That is a determination that we make not only in the authorisation but also in the post-market monitoring through our pharmacovigilance of any therapeutic good with the inclusion of vaccines. In terms of trust, we recognise that there is an active campaign to undermine the trust of regulators, the TGA particularly. We undertake to restore or bolster the trust of the public, which I have to say was during the pandemic and is still, despite some narratives, at a high level. We seek to do that through education and guidance. We do that through being very clear and transparent about what we do and by addressing dis- and misinformation when and if it occurs.
Senator ROBERTS: How many vaccines in the Australian schedule have been subject to a gold standard trial, meaning specifically a randomised double blind placebo control study where the placebo is saline and not another vaccine?
Prof. Lawler: I recognise that you weren’t here before lunch. We had a conversation with Senator Antic regarding the use of the term ‘gold standard’. We recognise that the use of a placebo control randomised double control trial—there are a number of different terminologies used—is of a very high standard and presents robust and dependable evidence. The challenge, of course, is whether something constitutes a gold standard in the way that you have used it. It actually very much depends on context. We use controlled or blinded trials or placebo trials when we are interested in determining the difference between a control arm and an intervention arm. This is really effective when we’re looking at incremental improvements in therapies or when we’re looking at the introduction of new therapies. The challenge we have, of course, is that when there is an established therapy that has been shown over decades using both documented and real-world evidence to be both safe and effective, it is ethically questionable—and, in some instances, ethically indefensible—to use a placebo in that non-intervention arm. I will give you two examples, if I may. We have vaccine preventable diseases, and we have a very clear demonstration of reduction in not only mortality but morbidity in those diseases. Let’s choose polio and small pox, diseases that have had a specific impact for many decades and have led to untold suffering. One of them has been eradicated by the use of vaccines and one of them has been virtually eradicated. If we were to introduce placebo controlled trials for those drugs, that would be horrendously unethical. We would be essentially and knowingly infecting children with a disease that could kill, paralyse or maim when we know that there is a way of preventing that. That’s not ethically defensible.
Senator ROBERTS: What you are saying is that there has been no double blind placebo control study where the placebo was saline and not another vaccine?
Prof. Lawler: No. What I am saying is that would not be an appropriate approach to be taking today with the vaccines we use.
Senator ROBERTS: Has it been taken in the past?
Prof. Lawler: I also would highlight that the introduction of vaccines occurred some time ago. And also—
Senator ROBERTS: So it has not been done?
Prof. Lawler: I will let you finish.
Senator ROBERTS: So it has not been done, then, the tests?
Prof. Lawler: Whether these—
Senator ROBERTS: A double blind trial?
Prof. Lawler: Well, we’ve actually already taken on notice to provide concrete evidence on which of those vaccines has been subjected previously to blinded control trials.
Senator ROBERTS: How many COVID vaccines have been destroyed because they aged out? What was the purchase cost for those products?
Prof. Lawler: Dr Anna Peatt from the national immunisation division will respond to that.
CHAIR: This is your last question, Senator Roberts.
Dr Peatt: Senator, could you please repeat the question? I didn’t quite hear it.
Senator ROBERTS: Certainly. How many COVID vaccines have been destroyed because they aged out? What was the purchase cost for those products?
Dr Peatt: Senator, I would have to take that question on notice. I don’t have that available with me today.
Senator ROBERTS: Was close to 35 per cent of the multibillion-dollar COVID vaccine supply binned or trashed?
Dr Peatt: I would have to take that question on notice.
Senator ROBERTS: I am asking for you specifically to tell us whether or not it was 35 per cent.
Dr Peatt: I don’t have that figure in front of me.
Senator ROBERTS: I am asking for you to just say what the figures are. Can you confirm that is 35 per cent of what we bought?
https://img.youtube.com/vi/uj4SbhAiGMU/maxresdefault.jpg7201280Senator Malcolm Robertshttps://www.malcolmrobertsqld.com.au/wp-content/uploads/2020/04/One-Nation-Logo1-300x150.pngSenator Malcolm Roberts2025-10-22 18:08:302025-10-22 18:08:37A Case Study in Avoidance
In the July sitting, the Albanese Government introduced the Health Legislation Amendment (Improved Medicare Integrity and Other Measures) Bill 2025. Most of the bill was a tidy-up of poorly drafted health legislation from the previous parliament.
However, one section was slipped in — a new power allowing the Therapeutic Goods Administration (TGA) to declare a drug shortage based merely on the suspicion of a future shortage. This would then enable the approval of drugs that haven’t been properly tested or assessed.
The TGA already has a similar power with a higher threshold for approval. This new legislation appears to be nothing but a pretense to give the TGA sweeping authority to bypass safety testing and scrutiny for new drugs. Even under the current “higher bar,” Section 19(1) has been used to approve 135 current drugs and 600 expired or lapsed ones — a total of 735 approvals of new drugs – or versions of drugs in two years.
I asked the Minister to provide an example of how Australians might be disadvantaged without these new powers. The Minister couldn’t answer. So I must ask — who actually wrote this? It clearly wasn’t the Government.
One Nation will repeal Section 19(1) and ensure that every new drug is subject to proper safety testing and full regulatory oversight.
Watch the video and see for yourself how clueless this Government is.
Transcript
Senator ROBERTS:Minister, the existing wording of section 19(1) already allows the TGA to approve the use of a drug that is not registered or approved in Australia, in the event of a shortage. That power has been used for 135 current approvals, and for 600 expired and lapsed approvals, for a total of 735 approvals of new drugs or versions of drugs in two years. Why do you need new powers when the existing wording is clearly no barrier to approval?
Senator McALLISTER(New South Wales—Minister for the National Disability Insurance Scheme): Thanks for the question, Senator Roberts. The advice that I’ve been provided is that the amendment goes to the ability to act in advance of a shortage arising—knowing that a shortage is coming towards us down the pipeline rather than being required to wait until the shortage actually arises. It will allow the government and the authorities to get ahead of shortages in relation to pharmaceuticals.
Senator ROBERTS: Thank you, Minister. Minister, can you provide an example of a situation where this new power would be needed because the old wording did not provide for that situation?
Senator McALLISTER: Senator Roberts, I think I’ve explained the principle, which is that from time to time we know that shortages of pharmaceuticals do arise. They arise because of interruptions to global supply chains or, sometimes, an interruption in a particular facility’s manufacturing capability. That disruption doesn’t immediately translate into a shortage, but we know, logically, that it will at some moment. These provisions allow us to get ahead of that situation.
Senator ROBERTS: My previous question was theoretical, to understand the process that informed the legislation. This question, Minister, is not theoretical: in what situation has the existing wording of section 19(1) failed to provide a good outcome for everyday Australians? Could you give me a real example, please?
Senator McALLISTER: There are multiple shortages that are managed by the TGA, and we want to be in the best possible position in the future to be able to manage them as they arise.
Senator ROBERTS: Just one example, please, Minister—not a theoretical one, not a hypothetical; just one concrete example of where this has been needed in the past and was not available.
Senator McALLISTER: Senator, it’s not my intention to trawl over previous decisions and circumstances, but it is the case that, from time to time, we can see in advance the potential for a shortfall, and we want to give the TGA the best possible opportunity to be able to intervene and make sure that the medicines that Australians need are available.
Senator ROBERTS: That seems to be confirmation, Minister, that it has not happened in the past. There’s no need for it.
Senator McALLISTER: That doesn’t follow from the advice I’ve provided to you, Senator Roberts. There are shortfalls from time to time in medications that are important for Australians. The TGA presently acts to manage those and works very actively. We want to make sure that, in future, they have all of the tools available to them to be able to do that, and we consider this to be an important amendment that will assist the TGA in that task.
Senator ROBERTS: Minister, thank you. You say that there are examples, but you won’t give me any, so let’s move on. Under this new low bar for approval, a pharmaceutical company would be tempted to avoid applying for a regular approval, which is expensive and time consuming, when they could just have their drug waved through under a spurious scarcity rumour—not fact but pending scarcity. Minister, what safeguards are in this legislation to ensure that big pharma does not create a false scarcity story to avoid making a normal authorisation application?
Senator McALLISTER: The TGA relies on intelligence; the TGA does not rely on rumours. The premise of your question is incorrect. It remains my position, as I’ve explained a number of times now, that it’s really important that we are able to act when we are aware of a forthcoming shortage or the possibility of a shortage of critical medicines. Australians rely on the availability of these, and it’s an important function that the TGA serves in protecting the supply chain.
Senator ROBERTS: Minister, this is getting to be disappointing. You keep telling me there are many examples and it’s concrete, but I don’t get anything. Let’s move on. Minister, under this bill, is there a time limit for the approval, and, if so, can the approval be renewed at the end of that period, creating what is, in effect, a permanent approval where they just keep extending it?
Senator McALLISTER: Senator Roberts, when you’re speaking about an approval, which particular approval are you referring to? Obviously, the legislation canvasses quite a range of different approvals.
Senator ROBERTS: Any temporary approval.
Senator McALLISTER: The advice I am provided is that the approval, by its nature, is temporary and expires as the shortage is resolved.
Senator ROBERTS: So, if the shortage is not resolved, is there a time limit for that approval to be enforced? If there is, can it automatically be renewed—in other words, granting a bypassing of the normal full regulatory approval process?
Senator McALLISTER: I appreciate the senator waiting while I obtain advice. I want to give accurate information to the Senate. The advice I’ve been provided is that these are statutory criteria that need to be met for any approval, and the TGA would need to be satisfied that those statutory conditions were met. However, it is the case that, ordinarily, these circumstances resolve themselves, so we do see shortfalls from time to time, and they are generally resolved over time. Our interest is making sure that any short-term shortages or impacts on Australians can be managed and that the TGA has the tools to do so.
Senator ROBERTS: So, Minister, is there a time limit and is it automatically renewed if the shortage continues beyond that time limit?
Senator McALLISTER: The advice that I have is that the approval would be provided with a time limit. That doesn’t prevent a reconsideration of the same questions, but it would be against the same criteria that I referred to in my earlier answer to your question.
Senator ROBERTS: So it’s highly likely we would just continue. The TGA has already approved certain drugs, including the product Pfizer sells as a COVID vaccine—their word. It’s already been approved for full TGA approval based, according to the TGA, on the safety profile data experienced during emergency use authorisation. Minister, will this legislation provide yet another way big pharma can make an end run around Australia’s longstanding authorisation process?
Senator McALLISTER: No. That’s a very leading question. The purpose of the legislation is set out in the explanatory memorandum and in other documentation around the bill, and there has been a Senate inquiry into the bill. Our objective is to make sure that Australians have the medicine that they need, even when shortfalls arise globally, and that we are in the best position to manage any consequences when we do see interruptions to global supply chains.
Senator ROBERTS: Of the 735 drugs granted authorisation under the existing legislation, how many are now subject to an application for full approval or have been approved based, according to the TGA, on the adverse events profile of the drug during approval under section 19(1) in the same way Pfizer’s Comirnaty was?
Senator McALLISTER: I am not in a position to confirm the numbers that you’ve cited in your question, nor do I have information about the numbers of applications on foot in various processes administered by the TGA. Perhaps you might like to think about another way of getting to the information that you’re interested in.
Senator ROBERTS: I will ask again and will try and break up the question: of the 735 drugs granted authorisation under the existing legislation, how many are now subject to an application for full approval?
Senator McALLISTER: As I indicated to you, Senator, I don’t have that information with me, nor would you expect me to. It’s a very detailed question.
Senator ROBERTS: Okay, I won’t continue with the other breakdowns of the question. Let’s move on to the next question. Does a drug approved under section 19(1) also go on the Pharmaceutical Benefits Scheme and, if so, does the normal negotiation on price still occur, or do we just pay whatever the drug company wants us to pay?
Senator McALLISTER: Thank you for waiting, Senator Roberts. I was seeking advice, again so that I can provide you with accurate information. The advice I have is that the standard process is for a medicine or product to be listed with the ARTG first before being considered by the PBS.
Senator ROBERTS: Thank you, Minister. The TGA have been enjoying unrivalled, unquestioned and unaccountable power since the start of COVID. Minister, why is the government extending the powers of the TGA again, with a bill that provides zero parliamentary oversight of the new powers?
Senator McALLISTER: I don’t agree with many of the propositions that are embedded in your question, Senator Roberts. I think I’ve been really clear about the purpose of the bill, or at least the elements which you’re asking me about now. Your very first question was: why do we need these additional provisions and abilities for the TGA? The answer is: from time to time we see shortages arise, where interventions are required to protect the interests, particularly the health interests, of Australian consumers. We want to make sure that the TGA has the capacity to manage these kinds of shortfalls.
Senator ROBERTS: Thank you, Minister. I appreciate what you just said; I don’t agree with it at all, because the TGA has run roughshod over the people of Australia when it comes to health. They are not held accountable. We need to return, in my opinion, to the days when the department of health approved or did not approve a drug and then the department could be held accountable to the parliament. That’s not the case for the TGA. It completely bypasses the parliament. So I foreshadow my amendment to introduce a provision to the existing legislation that any approval issued under this legislation must be by way of legislative instrument to allow parliamentary scrutiny. We, not the TGA, represent the people. The TGA has so many close contacts and close conflicts of interest with big pharma. It gets 96 per cent of its revenue from big pharma. Minister, why is there so little parliamentary oversight of our health bureaucracy?
Senator McALLISTER: Senator Roberts, I think you and I have different views about the level of oversight. The TGA is part of the department of health. The department of health appears regularly at Senate estimates. There are also a range of forums in which the parliament may ask questions about these issues, including, of course, in this place, in our own question time. Our government is committed to scrutiny, and I simply disagree with the proposition that you have made in your question just now.
Senator ROBERTS: You’re welcome to disagree, Minister. I’m sure that you welcome my disagreement. We saw the previous head of the TGA, Professor John Skerritt, retire from the TGA and, eight months later, get a job on the board of Medicines Australia, the big pharma medical lobby in this country. We also see that the TGA gets 96 per cent of its revenue from big pharma. That is a reason why we need to take the approval of drugs away from the TGA. Big pharma is not trusted, and, by association and due to their COVID mismanagement, we don’t trust the TGA anymore. I move One Nation amendment (1) on sheet 3379 as circulated:
(1) Schedule 2, Part 6, page 22 (line 1) to page 23 (line 22), omit the Part, substitute:
Part 6—Therapeutic goods approvals
Therapeutic Goods Act 1989
52 Subsection 19(1)
Repeal the subsection, substitute:
(1) The Secretary may, by legislative instrument, grant an approval to a person for the importation into, or the exportation from, Australia or the supply in Australia of specified therapeutic goods that are not registered goods or listed goods:
(a) for use in the treatment of another person; or
(b) for use solely for experimental purposes in humans;
and such an approval may be given subject to such conditions as are specified in the instrument.
Note: For variation of an approval for use of the kind referred to in paragraph (1)(b), see subsection (4B).
(1AAA) A legislative instrument made under subsection (1) must set out the reasons for the approval.
53 Subsection 19(4B)
Omit “by notice in writing”, substitute “by legislative instrument”.
Senator RUSTON (South Australia—Deputy Leader of the Opposition in the Senate): I would like to make a couple of comments on the contribution that Senator Roberts has just made in relation to his amendment to this particular bill. I probably would have a great deal of sympathy with Senator Roberts’s position, particularly after the comment made by the government that they’re committed to scrutiny. I don’t think anything could be further from the truth, when we’ve seen the amount of times that transparency has been denied in this place. In fact, this morning we had a half-hour contribution about the refusal of this government to be transparent when it comes to the NDIS. So I certainly have a great deal of sympathy with Senator Roberts in relation to the lack of scrutiny of their actions that the government are largely prepared to allow this parliament and the Australian public over their time in government.
But, in saying that, I understand that one of the most critical issues facing Australia in recent times has been drug shortages, for a number of reasons, of medicines and treatments coming into Australia. As a legislature, whilst safety and efficacy are at the forefront of every decision we make in relation to providing treatments and access to treatments for Australians through the necessary processes that exist within the department of health—and that includes through the TGA—one of the things we must always do is make sure that there is quick access because we know that so many Australians rely on treatments.
When there are shortages, the government must be able to act with some haste to put supplementary or substitute treatments and medications in place to ensure that Australians are not denied the life-saving and life-changing treatments they often rely on. At no time should safety ever be compromised for Australians, but we do understand that many Australians rely on the agility of our health department and its agencies to do that. But we acknowledge the lack of scrutiny and the lack of transparency that have become a hallmark of this government.
Senator McALLISTER: I’d like to indicate the government’s voting position. As I understand it, Senator Roberts’s amendment seeks to essentially require certain decisions to be made by way of a legislative instrument rather than by notice of writing. The government consider that this would be unnecessarily burdensome and would deprive the TGA of the flexibility that is necessary to manage the health interests of Australians, and we won’t be voting in favour of Senator Roberts’s amendment.
The CHAIR: The question before the chair is that amendment (1) on sheet 3379, moved by Senator Roberts, be agreed to.
https://img.youtube.com/vi/HfuEERh_KRQ/maxresdefault.jpg7201280Senator Malcolm Robertshttps://www.malcolmrobertsqld.com.au/wp-content/uploads/2020/04/One-Nation-Logo1-300x150.pngSenator Malcolm Roberts2025-08-19 08:55:112025-09-04 22:49:41Is This a Backdoor for Big Pharma?
I spoke with Brent on 2SM about to the recent and concerning medical emergencies involving commercial airline pilots and the disturbing lack of accountability from CASA regarding the impact of vaccine mandates on aviation safety.
We need proper cardiac screening and transparency about potential vaccine injuries among pilots. The public deserves to know the truth about what’s happening in our skies.
CASA’s wilful blindness to these serious safety issues must end.
Transcript
Brent: I said we were going to be talking to Malcolm Roberts this morning. He is on the phone. Two recent medical emergencies involving commercial airline pilots, one who collapsed in the cockpit, another who suffered chest pains mid-flight, have sparked fresh questions around aviation safety and pilot health post-Covid. Now, pilots, if you remember, were required to be vaccinated during the pandemic. Remember, no jab, no job. That’s what they were saying. No jab, no job. But could there be lingering medical issues going undetected? And are the regulators doing enough to stay ahead of it? Senator Malcolm Roberts raised the matter during Senate’s estimates. He joins me now. Good morning, Malcolm.
Malcolm Roberts: Good morning, Brent. How are you?
Brent: I’m well. Thank you for taking the time in your busy schedule. We really appreciate it. Okay?
Malcolm Roberts: You’re welcome. Pleasure.
Brent: When you asked about these incidents in Senate estimates, what was CASA’s response and did you get the sense that they’re really taking it seriously?
Malcolm Roberts: No, they’re definitely not taking it seriously. Their response echoed or exuded the word indignant. They’re indignant. I’ve asked them many questions about the vaccine injuries, the jab injuries, Fred, and they have been willfully blind, in my opinion. That’s my honest opinion. They have given me nothing. When I first asked about the jabs being mandated by Qantas and Virgin, they said, “Well, that’s their business.” They are responsible for any new medication coming into the airline sector to be tested at low altitude. That has not been done. When I asked them on whose advice they ignored Qantas and Virgin’s jabs, they said, “The experts.” On whose advice did you basically approve the vaccines? The experts. Which experts? The experts. Which experts? The experts. Which experts? The international experts. I never got a name. They will not take responsibility, that’s why I say they’re willfully blind. And we know from pilots, Fred, that there are many with serious problems.
Brent: Pilots already undergo regular medical checks, but is there a case for adding cardiac screening now, just as a precaution, given what we know post-Covid?
Malcolm Roberts: Yes, and we know that in states, the United States of America, the screening levels were increased considerably just to get more people through. I know from talking to a lawyer who’s helping a whistleblower prosecute Pfizer, that he was told by a Southwest Airlines pilot and Southwest Airlines is the biggest domestic carrier in the United States with about 23% of the market, almost a quarter. They tell me that 1,000 Southwest Airlines pilots failed their medical.
Brent: A thousand?
Malcolm Roberts: A thousand. We worked that out on back of envelopes stuff to be about 5%.
Brent: Gosh.
Malcolm Roberts: 1/20th. So there’s a serious issue, and we’ve heard from Australian pilots that there are people who are damaged who are flying, but they won’t report because they could lose their jobs.
Brent: The U.S. Defence study back in 2021, it raised concerns about myocarditis in young fit people including pilots. Shouldn’t that have been a trigger for more action here? Malcolm?
Malcolm Roberts: Definitely. But no matter what we raised with CASA, they just ignore it. They ignore the regulations about testing, requiring testing of new medications at low pressure, low and [inaudible 00:03:25] high altitude. These are significant rules that they’re just ignoring. They’re not taking responsibility for doing their job. I find CASA and in particular, it’s chief expense to be uncaring, and I don’t think they’re doing their job properly. That’s my honest opinion. They just seem to run away from their responsibilities. She is the top of the heap when it comes to airline safety in this country and she, in my opinion, she’s not behaving responsibly.
Brent: U.S. flight surgeon, Teresa Long sounded early warnings about health, heart risks with these mRNA vaccines. Malcolm, has there been any similar discussion or concern raised by aviation doctors in Australia?
Malcolm Roberts: Pilots have raised it with me. Former pilots who refused to get the jab who still stay in touch with their former colleagues have raised it with me. They’re very, very concerned about this. Very concerned. There have been doctors and pilot officials who’ve raised it with me, as well.
Brent: Do you think the public would be reassured if little word, big meaning, CASA simply looked at a short-term cardiac screening programme for pilots just to be on the safe side of things?
Malcolm Roberts: Yes. And what’s the fear about this? If a pilot is found to be liable or more prone or has a heart problem, then the public is going to be safe, safer by giving him treatment. That’s the first thing. If they find no one at all, and I don’t think that’ll be the case, then at least we’ve had that confirmed and the public can be at ease. But one of the things is they’re afraid to the whole, when I say they, it’s not just CASA, it’s the whole health establishment are afraid to do that because once they find the data themselves, they can’t ignore it, then they’d have to admit to what they did was inhuman by mandating untested, not properly tested vaccines in this country. So people are just burying it. I mean that sincerely. People in the health departments there at state and federal level, health agencies like APRA they’re burying this. They don’t want to.
Brent: So is it fair to say that CASA-
Malcolm Roberts: I hope we’re not going to be burying passengers soon.
Brent: Is it fair to say that CASA is just deliberately covering up myocarditis cases?
Malcolm Roberts: I would say that they’re in group think, they don’t want to admit it and it’s willful blindness. So you interpret that as deliberate in my view, they’re being deliberately negligent, which is deliberately not wanting to look at it because of what they might find, and I don’t think they know it, but medical authorities know that there’s a lot of heart problems with the vaccine with those vaccinated with the Covid shots.
Brent: Senator, this isn’t about panic, is it? It’s about trust.
Malcolm Roberts: Absolutely. It’s about trust, responsibility, and accountability. And the federal government, state government, we have got a problem in this country. The number one issue in this country, Fred, is that there is very low level of accountability. When I square up at Senate estimates, I’m holding them accountable and the liberal and labour governments, which I’ve had experience with both, they’re not on the side of the public. The number one problem in this country is shoddy governance that is based on ignoring the hard data, the hard evidence,
Brent: Trying to dust it away, hide it under the rug, as they say. Look, more transparency and a few extra checks would go a long way in keeping people confident when they simply step on a plane.
Malcolm Roberts: Yes, we’ve had senior pilots telling us that they admittedly retired rather than face the mandates or who voluntarily just refused to accept the mandates. They are very, very concerned and we know that the heart injuries globally from these shots, and it’s not just Astrazeneca, it’s also Moderna, also Pfizer. They have seriously raised a sign, raised the incidence of heart problems.
Brent: No jab and no job. That was the saying during this whole thing. No jab, no job, so we lost lots of excellent pilots. May I ask you, in your experience and the people that you talked to, have you found that because pilots lost their jobs, there’s a shortage of good pilots? Are pilots that didn’t take the jab, are they now getting their jobs back?
Malcolm Roberts: I don’t know. I make statements only based on data and I haven’t got the data with me on that, but I do know, I know the data that we have lost many, many fine nurses, paramedics, ambulancemen, doctors, firees, police officers. We have got some people who deliberately avoided the mandates and stood down or resigned or worse, stood down. We had a bloody nurse pregnant, stood down in January. Some of these places have still got mandates on and it’s basically inhuman. They didn’t test the shots properly, Fred, we know that they didn’t test them, yet, they mandated them and they said basically to people employed in all those industries and services that I just listed, they said basically, “If you want to feed your kids, you’ll get the shots.” That is inhuman. That is just disgraceful.
Brent: Did you say you had a nurse? I just want to repeat this, you had a nurse in January of 2025, she lost her job. Is that right? Because she hadn’t had a jab in 2025.
Malcolm Roberts: Sorry, January, 2024. My mistake. January, 2024.
Brent: Okay.
Malcolm Roberts: Yes. And she was basically suspended at work, off work suspended at various times in the previous three years since the jabs came in, the mandates came in and then they sacked her.
Brent: Gosh, we’ve just got to get rid of these mandates.
Malcolm Roberts: And the injections that were approved provisionally for people in this country, the medical authorities in this country are now saying healthy infants, children’s and adolescents aged less than 18 years of age are not recommended to receive Covid-19 vaccine.
Brent: Absolutely. They’ve changed their mind.
Malcolm Roberts: Yeah, so we’re going to see the TGA, we’re going to see APRA blacklisted from social media like I was suspended for saying exactly that healthy infants, children, adolescents should not be given the shots, I was blacklisted, suspended from social media. Are they going to be suspended? There’s not even a fuss about it. We know that Astrazeneca’s been withdrawn because of the court decision in the United Kingdom.
We need a royal commission. We need a royal commission to get to the bottom of this because there is a lot of lies being told, a lot of inhuman decisions, and now we find out that so many things, the premiers are telling us so many things in the Covid response, a fraudulent Covid response, are wrong and they’re not based on the science. They’ve admitted that, and we knew that because the different states had different approaches and some states had different approaches from one day to the next. They didn’t follow the data. There is no scientific evidence, empirical hard evidence. There’s been no serious testing. Pfizer cancels its tests early because they were killing people in their own test group who’d got the shots, and I asked the TGA, the Therapeutic Goods Administration responsible for provisionally, approving the shots in the first place, what testing they did. Oh, Senator Roberts, we didn’t do any testing. We relied upon the FDA in America, the Food and Drug Administration, which does America’s approvals.
And we knew at that time, Fred, at the time, the TGA told me that, we knew that the FDA had not done any tests and relied purely on Pfizer’s evidence. Pfizer’s evidence, and Pfizer is now being questioned seriously about the efficacy of the test. We’ve had tens of thousands of, let’s be blunt homicides, they are homicides, in this country and millions worldwide homicides because the testing has not been done properly at all. What testing was done was not proper at all. It was very, very brief.
Brent: All right, Malcolm Roberts, we’ll leave it there today. As always, thank you for making yourself available to talk on the Chris Smith morning show. Chris will talk to you again. No doubt. Keep up the good fight, Malcolm.
https://img.youtube.com/vi/2vWM0fq7VzI/maxresdefault.jpg7201280Senator Malcolm Robertshttps://www.malcolmrobertsqld.com.au/wp-content/uploads/2020/04/One-Nation-Logo1-300x150.pngSenator Malcolm Roberts2025-06-26 17:34:402025-06-26 17:34:59Time for Transparency: Aviation Safety Demands Answers from CASA
The largest ever study (QoVAX) comparing COVID injected to non-injected patients has been stopped without explanation, and Queensland Health is on track to destroy all of its samples and evidence.
Losing the last evidence that could inform a truly objective assessment of the effects of the injections wouldn’t just be a tragedy, it could be a crime.
I’m putting Queensland Health bureaucrats on notice. Do NOT destroy these samples and evidence – allow the study to complete so that the data can be shared for all Australians.
Transcript
This building could become the biggest crime scene in Australia.
I’m standing outside the Queensland Royal Brisbane and Women’s Hospital, Metro North, where Queensland Health intends to cover up and destroy evidence of the COVID vaccine fraud.
In 2021, a major research project, the QoVAX study, started researching 10,600 biospecimens from donors injected with the COVID-19 injections and from donors not injected.
The study was considering effectiveness and outcomes of being injected versus non injected.
It was to be the largest study of this nature in the world to date.
After only 18 months, the $20 million programme was shut down suddenly and without warning and with no valid reason provided. The donors were not even consulted, and neither were senior scientists running the study.
Metro North now intends to destroy the data and specimens, even though they’ve been informed of pending legal action to preserve the valuable data and evidence in the samples and material.
Destroying the samples would be a crime. Punishment for all responsible could include gaol time and massive fines.
The Human Research and Ethics Committee and board members of Metro North are failing in their duty and oversight responsibilities. This may make them culpable.
Why do these bodies wish to destroy the samples and data? What are they trying to hide?
Papers are about to be completed and published for the first 18 months of the research. If the research reveals problems with the COVID shots, it would embarrass Queensland Health bureaucrats and politicians. That’s motive for destroying the samples and the evidence.
If the research reveals no problems with the shots, why would Queensland Health not release the data and conclusions?
With a $4 billion annual budget, Queensland Health’s Metro North can afford to continue storing the samples and preserve the data.
I call for this decision to be immediately withdrawn and steps taken to preserve the specimens and reinstate this vital programme to provide conclusions as to the nature and effects of the COVID injections.
I’m sending letters to raise this issue with the Premier of Queensland, the Minister for Health and the Attorney General.
This is just another reason why Prime Minister Anthony Albanese must call a royal Commission into the entire COVID response.
Letters to Queensland’s Premier, Attorney-General and Minister for Health
https://img.youtube.com/vi/8JT2TyqPBSk/maxresdefault.jpg7201280Senator Malcolm Robertshttps://www.malcolmrobertsqld.com.au/wp-content/uploads/2020/04/One-Nation-Logo1-300x150.pngSenator Malcolm Roberts2025-05-22 18:11:002025-05-22 18:12:56Crime Scene in the Making: Hospital Moves to Destroy COVID Vaccine Data
Dengue fever is a viral illness spread by the Aedes aegypti mosquito (known as the dengue mosquito in north Queensland). The dengue virus is not endemic in Australia, meaning the virus is not normally present in Australia.
Dengue fever outbreaks begin when someone is infected with dengue overseas and arrives with the virus in their blood. This is referred to as an imported case. When a local Aedes aegypti mosquito bites an infected person, it in turn becomes infected with the virus and can then transmit it to others through subsequent bites. These instances are known as locally acquired cases.
The dengue virus does not spread directly from person to person.
Catching different types of dengue, even years apart, increases the risk of developing severe dengue. Severe dengue causes bleeding and shock, and can be life-threatening. There have been deaths in Queensland from severe dengue. This is why a vaccine is problematic, because that relies on giving the subject the disease.
About Oxitec and Their Process
Oxitec’s genetically modified mosquitoes work by releasing sterile males into the wild to mate with females, which results in offspring that die in the larval stage. Oxitec’s mosquitoes are engineered with a self-limiting gene that produces a non-toxic protein that prevents their offspring from surviving to adulthood. The protein, called tTAV, disrupts the cell’s ability to function and prevents the insect from developing normally.
The gene can be switched off using amoxicillin, which allows the factory to breed the mosquitoes, then once in the wild, the amoxicillin wears off and the gene starts producing the protein again.
In short – it’s gene editing, hence the need for the application to the Office of the Gene Technology regulator.
“Launched today, Oxitec Australia is a collaboration between CSIRO, Australia’s national science agency, and UK-based Oxitec Ltd, the leading developer of biological solutions to control pests.“
And look who is running the show – “Professor Brett Sutton, Director of Health & Biosecurity at CSIRO, said Oxitec Australia is now seeking partners to accelerate its activities and product development in Australia.”
When I said it was a template, this is confirmed in the CSIRO press release:
“This technology platform could also be used to develop solutions for a wide spectrum of pests that threaten livestock and crops and our food systems.”
Oxitec are running field trials on a fall armyworm with the same gene added, which is a moth not a mosquito. And it’s our money going into this so Estimates is fair game:
“Oxitec Australia is also developing an Aedes albopictus (Asian tiger mosquito) solution, with funding from CSIRO, to help prevent a major invasion risk to mainland Australia. “
Mosquito Performance in Brazil
Oxitec launched a year-long field trial in Indaiatuba, Brazil in 2018. The trial involved releasing Oxitec’s Friendly™ Aedes aegypti in four communities. The trial’s results included an average of 89% peak suppression in two communities treated with a low release rate of mosquitoes according to Oxitec. Brazil’s Dengue rate was low in 2018, and jumped up in 2019 and later. The locals are claiming a connection but there is no science around what that connection could be.
Gates Foundation however washed their hands of the Brazil Dengue escalation with this statement:
“A spokesperson at the Gates Foundation told AFP that the foundation ‘does not fund any of Oxitec’s work involving Aedes aegypti mosquito release in Brazil.’
NOT exactly a debunking of the controversy.
People are asking if the explosion in Dengue in Brazil the year after the trial was related, especially when the same thing happened after a similar trial for Zika. It is a question that should be addressed, although I do think it is not connected.
Florida 2021 – Nothing Went Wrong
Oxitec ran a controlled release in Florida in 2021. A kill rate of 90% was proven, with no known unintended consequences. HOWEVER, there was an increase in Dengue the following year and the same thing happened with the Zika test in Brazil. The reason this isn’t related is the genotype:
“We documented an unprecedented number of travel-associated and locally acquired DENV-3 cases in Florida during May 2022–April 2023; circulation of the DENV-3 genotype III was recently identified in the Americas. Our investigation illustrates that local transmission and spread in Florida was limited, despite multiple introductions from outside the country. Sequencing and phylogenetic analysis revealed that cases were from the same DENV-3 genotype III lineage and were highly related to one another and to cases identified in Puerto Rico, Arizona, and Brazil.”
So the outbreak was not spontaneous in the area of the trial, but was introduced from outside.
Dengue Vaccine and the Philippines Scandal
Sanofi Pasteur owns the Dengvaxia® vaccine – the first licensed dengue vaccine and available in more than 20 countries. It is registered with the Therapeutic Goods Administration (TGA) in Australia, but is not currently marketed here.
WIKIPEDIA: “The Philippine Department of Health began in 2016 a programme in three regions to vaccinate schoolchildren against dengue fever, using Dengvaxia supplied by Sanofi Pasteur. On 29 November 2017, Sanofi issued a caution stating that new analysis had shown that those vaccinated who had not previously been infected with dengue ran a greater risk of infection causing severe symptoms. On 1 December 2017, the Philippine DOH placed the programme on hold, pending review. Over 700,000 people had received at least one vaccination at that point.[11][12] Since the announcement by Sanofi, at least 62 children have died, allegedly after receiving a vaccination. The victims’ parents blamed the dengue vaccine for the deaths of their children.”
Most of the deaths were caused by internal bleeding in the heart, lungs and brain, which are symptoms of haemorrhagic dengue.
Is this an Attempt to Create a Disease Just to Sell the vaccine?
Comparison of death rates from the vaccinated and unvaccinated suggests the vaccine offers some benefit, but that is mostly based in areas and demographics where health services are poor. It is best answered by offering mobile health services in affected areas. This Australia can do, whereas maybe the Philippines can’t.
The vaccine is listed in Australia – but hasn’t been used. The Philippines incident was the last known use of the vaccine, and the victim’s court case is still underway. Given Sanofi’s admissions around the vaccine and WHO’s advisory that a serology test is needed before giving the vaccine to a person to ensure they haven’t had the disease before, I doubt this is a vaccine play.
The mRNA version of the vaccine was trialled and rejected in 2014 because it didn’t work. It’s not an attempt to feed work to Pfizer’s new mRNA factories in Australia. There are new vaccines coming through but they have the same problem – making the disease worse in people who have had it before.
Some Mosquitoes Replicate
4% of the mosquitoes in the Brazil test lived and replicated. No work appears to have been done on what happened to the offspring – were they normal or were they mutated and if so, what is the effect of that mutation?
Could a mutated progeny cause a mutation in the virus (Dengue, Zika, Yellow Fever, Malaria) which causes it to become more dangerous, infectious, etc. This is a major question to be answered – capturing and testing mosquitoes in the wild to look for mutations, and that work has not been done. It must be an element of the OGTR approval.
Mosquitoes have a life cycle of 7 – 10 days. Fall army worms (FAW) live 6 – 8 weeks, so they are present in the environment longer but not significantly so.
https://i0.wp.com/www.malcolmrobertsqld.com.au/wp-content/uploads/2025/01/Bill-Gates.jpg?fit=892%2C446&ssl=1446892Senator Malcolm Robertshttps://www.malcolmrobertsqld.com.au/wp-content/uploads/2020/04/One-Nation-Logo1-300x150.pngSenator Malcolm Roberts2025-01-29 12:09:422025-01-29 14:18:12Queensland Given the Green Light to Bill Gates-Backed Mosquito Trial
Aluminium adjuvants (preservatives) in vaccines are commonly blamed, at least in part, for the increase in autism. Recent work has been done that confirms this theory, so I asked the TGA about the subject. Research on aluminium was conducted on aluminium salts, but the jabs use a quite different type of aluminium which has not been safety tested. This is my exact question:
“A study published in September took biopsies from the brains of older children diagnosed with autism and found their brains contained significantly elevated levels of aluminium, especially aluminium hydroxide and aluminium phosphate, which are present in the hexa jabs. Has the health testing on aluminium build-up in our children’s bodies been done using water-soluble aluminium salts, which are not used in vaccine products, or has this research been done using the actual aluminium used in vaccine products, aluminium hydroxide and aluminium phosphate?”
This question was straightforward and simply put: have you tested the right type of aluminium for safety? The TGA feigned not understanding the question to avoid answering it. When pressed, they took the question on notice and then refused to provide further information, with Minister Gallagher covering for her bureaucrats. This is unbecoming for a senior bureaucrat and for the Minister.
Australians want an answer to this, and I will keep at the subject until I get one. The fact they are hiding from the question suggests the answer is as recent science is showing – aluminium preservatives in vaccines are causing autism in some children.
Transcript
Senator ROBERTS: My third and final set of questions is about aluminium adjuvants. Again, constituents are raising this. A study published in September took biopsies from the brains of older children diagnosed with autism and found their brains contained significantly elevated levels of aluminium, especially aluminium hydroxide and aluminium phosphate, which are present in the hexa jabs. Has the health testing on aluminium build-up in our children’s bodies been done using water-soluble aluminium salts, which are not used in vaccine products, or has this research been done using the actual aluminium used in vaccine products, aluminium hydroxide and aluminium phosphate?
Prof. Lawler: Sorry; did you reference research? There was a question there about whether research has been done?
Senator ROBERTS: Has the research been done on babies’ brains using the aluminium found in vaccine products, aluminium hydroxide and aluminium phosphate, or has it been done using water-soluble aluminium salts?
Prof. Lawler: Sorry; I’m just trying to be clear. Is the research that you’re asking me about the research that you cited?
Senator ROBERTS: No, I haven’t cited anything. To your knowledge, has the health testing on aluminium build-up in our children’s bodies been done using water-soluble aluminium salts, which are not used in vaccine products, or has the research been done using the actual aluminium found in vaccine products, aluminium hydroxide and aluminium phosphate Prof. Lawler: I’m sorry; I don’t know the research that you’re specifically referring to.
Senator ROBERTS: Okay. I’ll send you some papers. Is the type of aluminium in vaccine products bioresistant? Does it ever leave the bodies of our children?
Prof. Lawler: Again, there are a number of very specific and very technical questions that you’re asking us. For the purposes of answering them, as I’ve previously indicated, we’re very happy to take these questions—
Senator ROBERTS: That’s fine. I’ve got nothing against taking them on notice.
Prof. Lawler: Okay. I would like to provide you with as fulsome a response as possible.
Senator ROBERTS: Thank you. Are repeated doses of low concentrations of aluminium adjuvant in a vaccine product more harmful than a single large dose? A related question: how many vaccine products containing aluminium hydroxide and aluminium phosphate has the TGA authorised for administration to children? You’ll have to take that on notice.
Prof. Lawler: I certainly will have to take that on notice.
Senator ROBERTS: I only had a concern about the one I objected to. I have no concern about the rest at all. I appreciate that it’s a better answer. Individual vaccine products have been safety tested. Has any safety testing been done on multiple, concurrent administration of vaccine products to babies under six months, with special attention to multiple administration of low dose aluminium adjuvants?
Prof. Lawler: Professor Langham can add to this response. There has been not only significant research undertaken with respect to the administration of vaccines but there is significant real-world evidence over decades on the safety of the administration of the vaccines that we approve.
Prof. Langham: I have nothing further to add on that. As you’re aware, we have a number of avenues whereby safety signals from all registered products in Australia are overseen from a pharmacovigilance perspective, as Dr Larter has already mentioned. We work closely with other global regulators and also with other research that’s published. As Professor Lawler has said, with the vast body of information that exists about these vaccines and their use in children, there have been no signals.
Senator ROBERTS: So you can’t answer the question as to whether or not—
Prof. Langham: I think I did answer the question.
Senator Gallagher: Yes. I think that’s definitely an answer.
Senator ROBERTS: I’ll ask it again. Has any safety testing been done on multiple concurrent administration of vaccine products to babies under six months, with special attention to multiple administration of low-dose aluminium adjuvants? Can you tell me if multiple injections have a different effect from one or two injections?
Prof. Langham: The evidence that exists from a safety perspective is not only the clinical trial data that we receive upon registration but also the ongoing evidence from a real-world perspective of the use of these vaccines in those multiple dose formulations in many millions of children around the world.
Prof. Lawler: For many years.
Senator ROBERTS: I have a last question. Are aluminium adjuvants causing the spectrum of neurological conditions that are commonly called autism?
Prof. Lawler: I’m not aware of any accepted evidence that that is the case.
Senator ROBERTS: Minister, you may sigh—
Senator Gallagher: Do you know why I sigh, Senator Roberts? It’s because I have a child with autism, and I have vaccinated children, and I find it offensive.
Senator ROBERTS: Well, I find it offensive to not respond to a constituent, and I’m responding to constituents. That’s my job. They pay me.
Senator Gallagher: Well, I’ve had enough.
Senator ROBERTS: Professor Lawler, have you heard of these papers? I think this will be my last question, Chair.
CHAIR: Yes, it will be.
Senator ROBERTS: I’ve mentioned one by Dr Karla Lehmann from 2024 titled ‘Suspected Causes of the Specific Intolerance Profile of Spike-Based Covid-19 Vaccines’ in the European Society of Medicine. There’s one from 2022 by El-Arif G et al called ‘Angiotensin II Type I Receptor (AT1R): The Gate towards COVID-19 – Associated Diseases’ published in Molecules. In 2023 Fajloun and Sabatier published ‘The Unsuspected Role of the Renin-Angiotensin System (RAS): Could its Dysregulation be at the Root of All Non-Genetic Human Diseases?’ in Bentham Science. In 2023 Parry, P et al wrote, ‘”Spikeopathy”: COVID-19 Spike Protein Is Pathogenic, from Both Virus and Vaccine mRNA’ in Biomedicines (Journal). The last one is from Pelumbo, Avila and Naftolin in 2016 called ‘The Ovarian Renin-Angiotensin System (OVRAS): A Major Factor in Ovarian Function and Disease’ in PubMed by the National Institute of Health, the National Library of Medicine USA.
Prof. Lawler: I’d be very happy to receive those studies—I’ll speak on behalf of Professor Langham if she doesn’t mind. I would say that there is a very well established understanding of the importance of the renin-angiotensin-aldosterone system in a number of various elements of regulation of human function. I think it is well recognised that they are impacted by the COVID disease itself.
Senator ROBERTS: What part of the COVID disease?
Prof. Lawler: It will be very useful for us to review those articles so that we can be sure that they are reflective of the impact of COVID not, as suggested, an impact of the vaccine.
Senator ROBERTS: Good. Thank you very much. Would you like the references sent as paper copies, as attachments or by links?
Prof. Lawler: At your pleasure.
Senator Gallagher: Carrier pigeon.
Senator ROBERTS: Chair, I’ll be putting forward a number of questions on notice on the spike protein.
In a recent senate estimate session, I highlighted the alarming ethnic disparities in COVID-19 mortality rates. Australians from the Middle East died at three times the average death rate, those from Southern Europe twice as high, while sub-Saharan Africans had lower mortality rates.
What’s driving these disparities? The health experts suggest that low vaccine coverage and socioeconomic factors played roles in these differences. As vaccination efforts improved, mortality rates began to align more closely with the general population.
These are just theories, not explanations, and it comes across as a lazy response. There’s no justification for not making an effort to understand the reasons behind such a serious medical issue.
Transcript
Senator ROBERTS: Professor Kelly, you previously brought someone forward to talk about the differences in incidence and severity with a low-socioeconomic profile.
Prof. Kelly: Mr Gould, yes.
Senator ROBERTS: Australian residents from the Middle East died at three times the population mean, those from Southern Europe were twice as likely to die and those from North Africa were almost three times as likely to die; however, sub-Saharan Africans were less likely to die. Why are we seeing ethnic differences in COVID mortality in Australia? I understand that ‘ethnic’ is to do with culture.
Dr Gould: Yes. Just talking around the numbers involved, as you say, the ABS has reported, during various stages of the pandemic, mortality rates for people born in different countries and, as you’ve said, there are higher mortality rates for people born in places such as the Middle East. There are a number of potential reasons for that. One of the areas that I discussed in my previous answer, which I think is relevant, is that, for a lot of those communities, initially, vaccine coverage rates were low. So significant work was done during the course of the pandemic to work with those communities to increase the coverage rate, and we really saw quite a dramatic shift during the course of the pandemic in the variation in mortality rates between these communities in the general Australian population; to a large degree, they came into line with the general population experience, so that was a positive outcome. Certainly, there’s an indication that the vaccine rates would have had a role to play. We did talk as well about socioeconomic status. We do know that, for some language groups or groups born in different countries, those rates may correlate with different socioeconomic status as well, so there may be some relationships there.
Senator ROBERTS: So there’s an overlap, potentially, in some areas?
Dr Gould: Potentially, yes. It’s not broadly always the case. We find that a lot of recent, skilled migrants live in high socioeconomic areas, so it’s difficult to make a broad generalisation there.
As a Scientist and former vet school Dean, Professor Rose became concerned that critical information about SARs-CoV2 virus and COVID-19 vaccines was not being reported by mainstream media.
We discussed how the world and particularly Australia changed with the arrival of COVID and how the population seems to have forgotten the drastic restrictions that were put on our freedoms. We also discussed what, if any, lessons were learned.
Reuben received a notice from YouTube that he had “breached community guidelines” and the link to his channel can no longer be accessed.
https://img.youtube.com/vi/yxRWoySJHOY/hqdefault.jpg360480Senator Malcolm Robertshttps://www.malcolmrobertsqld.com.au/wp-content/uploads/2020/04/One-Nation-Logo1-300x150.pngSenator Malcolm Roberts2024-05-23 16:34:182024-05-23 16:34:23A Chat with Emeritus Professor Reuben Rose | Sons of Issachar
I was disappointed in the Minister’s response to my questions about the implications of the QLD Supreme Court judgement on the COVID ‘vaccine’ mandates. I expected more clarity and less deflection from the Minister. These decisions were made by the Liberal, Labor and Greens parties, there can be no avoiding the fallout form their actions across the COVID period.
While the ruling was made on the basis of the human rights act in QLD, identical provisions are in place in Victoria and the ACT, suggesting the decision is not just a QLD issue. The government is arrogantly ignoring the reality of the situation and failing to read the room when it comes to this topic.
People have had enough of high-handed, out of touch government. One Nation is calling for the Royal Commission into our COVID response to be announced right now!
Transcript
I take note of Senator Gallagher’s answer to my question on the Queensland Supreme Court’s decision. The court found measures relating to COVID were mandated on a number of Queensland workers without adequate consideration of their human rights as required under the Queensland Human Rights Act. Identical human rights provisions apply in Victoria and the ACT. So certainly there is the probability of the same or similar decisions being made in other jurisdictions.
I’d hoped the government would be fully aware of the implications of this decision. I was disappointed. The minister deflected and failed to address the substance of the question, so here are some more reasons the minister should get clarity on this issue. An employee who is fired as the outcome from a vaccine mandate can sue the employer, which may be the government, for wrongful dismissal. An employee who took a vaccine to keep their job as a result of a vaccine mandate, who is now vaccine injured, can sue for damages. Class-action lawsuits will result from this decision. The Commonwealth will be as much in the firing line as Victoria and Queensland.
It’s not just mandates. Evidence has been presented over the last few months that closing schools and denying children education has caused a permanent drop in children’s educational potential and medical health—permanent harm. Last week, a landmark study of 99 million people including Australians found the injections caused an increase in blood clots, brain injuries and heart disease of up to 600 per cent. These injuries are legally actionable. Whether it’s over mandates, vaccine injuries, education or business closures, victims will be joining class-action lawsuits sooner rather than later.
All levels of government in Australia made terrible mistakes during COVID. Only a royal commission has the powers and the resources to decide what mistakes were made and how the victims of those mistakes can be fairly compensated. This will be expensive, yet failure to act through a royal commission will create a running sore on public administration for a generation. Only an objective royal commission will restore trust in governments and in the healthcare sector.
